Assessing performance of clinical risk prediction models in the era of machine learning



Ben Van Calster KU Leuven (B); LUMC Leiden (NL)

**KU LEUVEN** 

ISCB, July 2024, Thessaloniki

# Binary outcomes: a lot of measures

The Measurement of Performance in Probabilistic Diagnosis III. Methods Based on Continuous Functions of the Diagnostic Probabilities

(From the Department of Public Health and Social Medicine, Erasmus University, Rotterdam,

(From the Department of Public Health and Social Measure, Erasmus University, Rolleraum The Netherlands, and the Institute of Human Genetics, University of Copenhagen, Denmark)

J. HILDEN, J. D. F. HABBEMA, B. BJERREGAARD

#### An experimental comparison of performance measures for classification

C. Ferri\*, J. Hernández-Orallo, R. Modroiu

Departament de Sistemes Informàtics i Computació, Universitat Politècnica de València, València 46022, Spain

Assessing the Performance of Prediction Models

A Framework for Traditional and Novel Measures

Ewout W. Steyerberg,<sup>a</sup> Andrew J. Vickers,<sup>b</sup> Nancy R. Cook,<sup>c</sup> Thomas Gerds,<sup>d</sup> Mithat Gonen,<sup>b</sup> Nancy Obuchowski,<sup>e</sup> Michael J. Pencina,<sup>f</sup> and Michael W. Kattan<sup>e</sup>

# Metrics Reloaded: Recommendations for image analysis validation

LENA MAIER-HEIN<sup>\*†</sup>, German Cancer Research Center (DKFZ), Germany, Heidelberg University, Germany, and National Center for Tumor Diseases (NCT), Germany

Hilden et al. Meth Inform Med 1978. Ferri et al, Pattern Recogn Lett 2009. Steyerberg et al, Epidemiology 2010. Maier-Hein et al, Nature Methods 2024 Stats focus

Machine learning focus

Stats focus

Machine learning focus



Topic Group 6: Evaluating diagnostic tests and prediction models

#### Performance measures for predictive AI in clinical medicine: a comprehensive overview

B VAN CALSTER, GS COLLINS, L WYNANTS, AJ VICKERS, G VAROQUAUX, KF KERR, K SINGH, M VAN SMEDEN, KGM Moons, T HERNANDEZ-BOUSSARD, D TIMMERMAN, DJ MCLERNON, EW STEYERBERG

# Case study: ovarian tumor diagnosis

Aim:

Externally validate the ADNEX model to estimate risk of malignancy of a detected ovarian tumor

Support decision whether specialized surgery is needed (threshold 0.1)

External validation dataset: n=894, 434 malignancies (49%)

Updating using logistic recalibration: Linear transformation so rank-preserving

# **Performance domains**

	Domain	Focus	Target question		
	Probability-based evaluation				
	Discrimination	Relative	Does the model estimate a higher probability in individuals with an event than individuals without an event?		
	Calibration	Absolute	Are probably estimates from the model reliable?		
Statistical	Overall	General	How close are estimated probabilities from the model (between 0 and 1) to actual outcomes (0 or 1)?		
	Threshold-depende	nt evaluation			
19	Classification	Binary	Are individuals classified correctly corresponding to their observed outcome?		
	Clinical utility	Clinical	Do classifications lead to useful decisions?		

**Decision-analytic** 

# Key desirable characteristics

Properness

Expected value of measure is optimized for correct model (fool proof)

#### **Clear performance focus**

Clear separation of statistical vs decisionanalytic performance




Domain	#	Measures	Plots
Discrimination	3	AUROC AUPRC (area under precision-recall curve) Partial AUROC	ROC curve Precision-recall curve
Calibration	6	O:E ratio calibration intercept Calibration slope Estimated calibration index (ECI) Integrated calibration index (ICI) Expected calibration error (ECE)	Calibration plot
Overall	Loglikelihood logloss (cross-entropy) Brier Scaled Brier (Brier Skill, IPA) 9 McFadden R2 Cox-Snell R2 Nagelkerke R2 Discrimination slope (coeff. of discrimination) MAPE		Risk distributions

Domain	#	Measures	Plots
Classification	11	SUMMARY MEASURES (7) Accuracy Youden index Balanced accuracy DOR Kappa F1 Matthew's Correlation Coefficient (MCC) PARTIAL MEASURES (4) Sensitivity (recall) Specificity PPV (precision) NPV	Classification plot
Utility	3	Net Benefit Standardized NB Expected cost	Decision curve Cost curve


Domain	Measure	Properness	Stat vs DA focus
	AUROC / concordance (c) statistic	Semi	ОК
Discrimination	AUPRC	Semi	Mixed
	Partial AUROC	Semi	Mixed
	O:E ratio	Semi	ОК
	Calibration intercept	Semi	ОК
Calibration	Calibration slope	Semi	OK
Calibration	Estimated calibration index (ECI)	Strict	OK
	Integrated calibration index (ICI)	Strict	OK
	Expected calibration error (ECE)	Strict	OK
	Loglikelihood	Strict	ОК
	Logloss/cross-entropy	Strict	ОК
	Brier score	Strict	ОК
	Scaled Brier / Brier Skill Score	Strict	ОК
Overall performance	McFadden R-squared	Strict	ОК
	Cox-Snell R-squared	Strict	ОК
	Nagelkerke R-squared	Strict	ОК
	Discrimination slope	Improper	ОК
	MAPE	Improper	ОК

Domain	Measure	Properness	Stat vs DA focus	
	Classification accuracy at t	Improper	ОК	
	Balanced accuracy at t	Improper	ОК	
	Youden index at t	Improper	ОК	
	Diagnostic odds ratio at t	Improper	ОК	
	Kappa at t	Improper	ОК	
Classification	F1 at t	Improper	Mixed	
Classification	Matthew's Correlation Coefficient	Improper	ОК	
	(MCC) at t			
	Sensitivity at t	Improper	ОК	
	Specificity at t	Improper	ОК	
	Positive predictive value (PPV) at t	Improper	ОК	
	Negative predictive value (NPV) at t	Improper	ОК	
	Net benefit	Semi	ОК	
<b>Clinical utility</b>	Standardized net benefit	Semi	ОК	
A ATA	Expected cost	Semi	ОК	


# Case study: risk distributions




### Case study: ROC and PR curves



### Case study: calibration plot



### Case study: decision and cost curves




# Case study: before/after updating

Domain	Measure	Properness	No recalibration	Recalibration
Discrimination	AUROC / concordance (c) statistic	Semi	0.911	0.911
	AUPRC (area under precision-recall curve)	Semi	0.895	0.895
	Partial AUROC	Semi	0.141	0.141
Calibration	O:E ratio	Semi	1.228	1.000
	Calibration intercept	Semi	0.810	0.000
	Calibration slope	Semi	0.934	1.000
	Estimated calibration index (ECI)	Strict	0.105	0.002
	Integrated calibration index (ICI)	Strict	0.094	0.014
	Expected calibration error (ECE)	Strict	0.091	0.017
Overall performance	Loglikelihood	Strict	-370	-337
	Logloss/cross-entropy	Strict	370	377
	Brier score	Strict	0.133	0.118
	Scaled Brier / Brier Skill Score	Strict	0.469	0.526
	McFadden R-squared	Strict	0.403	0.456
	Cox-Snell R-squared	Strict	0.427	0.469
	Nagelkerke R-squared	Strict	0.570	0.625
	Discrimination slope	Improper	0.509	0.525
	Mean absolute prediction error (MAPE)	Improper	0.243	0.237

Green: better Red: worse

# Case study: before/after updating

Classification	Classification accuracy at t	Improper	0.794	0.691
	Balanced accuracy at t	Improper	0.799	0.700
	Youden index at t	Improper	0.597	0.399
	Diagnostic odds ratio at t	Improper	37.4	43.3
	Kappa at t	Improper	0.592	0.392
	F1 at t	Improper	0.818	0.756
	Matthew's Correlation Coefficient (MCC) at t	Improper	0.625	0.480
	Sensitivity at t	Improper	0.954	0.984
	Specificity at t	Improper	0.643	0.415
	Positive predictive value (PPV) at t	Improper	0.716	0.614
	Negative predictive value (NPV) at t	Improper	0.937	0.965
Clinical utility	Net benefit	Semi	0.443	0.444
-	Standardized net benefit	Semi	0.912	0.915
	Expected cost	Semi	0.355	0.355



# "Confusion" matrix: it's in the name

How many measures are there to summarize a 2x2 table?!

The 7 measures we evaluated are improper at threshold *t* 

Reason: *t* implies specific misclassification costs, but these are ignored

Summary measures: no value to formally assess or compare performance Partial measures (sens, spec, PPV, NPV): good for description

17

KU L

#### Harmonic mean of PPV (precision) and sensitivity (recall)

#### **Fierce defenders**

"Furthermore, previous studies  $\frac{18,21,31}{1}$  have used AUC as the performance metric, rather than F1-score, which may have overestimated the respective model's performance at the classification of adnexal masses, given the lack of adjustment for class imbalance" (Barcroft, npj Precis Oncol 2024)

- F1 ignores true negatives
- F1 absolute value changes by switching the outcome labels
- F1 value cannot be interpreted
- F1 at threshold *t* is improper, like all classification measures

**KU LEU** 

### **Precision-Recall curve**

Alternative for ROC Plots PPV (aka precision) by sensitivity (aka recall)

"The PR curve overcame the optimism of the ROC curve in rare diseases" (Ozenne, JCE 2015)

AUPRC: ignores TN, depends on prevalence
AUROC: comprehensive and interpretable (~ Mann-Whitney)
it does not depend on prevalence (≠ overestimating)

AUROC does not tell the full story, but AUPRC does not solve this



**KU LE** 

# Matthew's Correlation Coefficient (MCC)

Pearson correlation of classifications and outcomes. (cf phi correlation)

Interpretation?

It will not help.





# Utility: net benefit or expected cost

NB uses the link between threshold and misclassification costs EC does not, it rather does logistic recalibration behind the scenes

NB: "misclassification costs imply t=0.1, so how useful is model at t=0.1?" EC: "OK, misclassification costs imply t=0.1, but cost minimized at t=0.06"



# Class imbalance is not a problem

Class imbalance: the two outcome classes are not equally common

Claims that some measures (AUROC, accuracy) are invalid/misleading because imbalance not considered AUPRC/F1 often recommended to 'overcome' this 'problem'

#### But:

- Class imbalance is not proportional to cost imbalance (conflation)
- Some measures are just improper (eg accuracy)
- We have utility measures to address this appropriately

Imbalance is a fact of life rather than a problem, so just deal with it

**KU LEU** 

# What measures/plots to use?

#### (Being discussed ATM)

Do not use measures that do not meet the 2 characteristics Generally, these seem the key ones:

- Show risk distributions (~ overall)
- Discrimination: AUROC
- Calibration: provide a calibration plot

(if the model is intended to support decisions)

- Classification: descriptive measures
- Clinical utility: NB or EC with plot

For the decision maker: Is the model potentially useful? For the modeler: How can we improve the model?